Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 18, 2020
Context: The filing reports a material corporate event regarding intellectual property rights for the company's drug candidate, Namodenoson.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes
Patent Allowance: On February 18, 2020, Can-Fite Biopharma Ltd. announced it was granted patent allowance in South Korea.
Subject: The patent is titled "An A3 adenosine receptor ligand for use in treating ectopic fat accumulation."
Asset: The patent covers the company's drug candidate, Namodenoson.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies beyond the announcement of the patent allowance.
Investor Verification Checklist
- Verify the scope and enforceability of the South Korean patent allowance for Namodenoson.
- Confirm the status of Namodenoson clinical trials and regulatory filings in other jurisdictions.
- Review the attached press release (Exhibit 99.1) for additional details on the patent's commercial implications.
- Check subsequent filings for updates on the patent's final grant status and any associated costs.